Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer

Drugs of Today

Volumn 49, Issue 9, 2013, Pages 523-535

  Bowles, D W ^a,b   Weickhardt, A ^c   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Afatinib; BIBW 2992; Dual inhibitor; EGFR; Non small cell lung cancer

Indexed keywords

AFATINIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; K RAS PROTEIN; LAPATINIB; NERATINIB; PACLITAXEL; PEMETREXED; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; COLORECTAL CANCER; CONTINUOUS INFUSION; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; FATIGUE; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; KIDNEY METABOLISM; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STOMATITIS;

EID: 84885202877     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.09.2016610     Document Type: Review

References (76)

1. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3): 183-232.
2. Citri, A., Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7(7): 505-16. (Pubitemid 44036456)
3. Mendelsohn, J., Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21(14): 2787-99. (Pubitemid 46606324)
4. Lewis, T.S., Shapiro, P.S., Ahn, N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74: 49-139. (Pubitemid 28193546)
5. Gullick, W.J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991, 47(1): 87-98.
6. Kuan, C.T., Wikstrand, C.J., Bigner, D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001, 8(2): 83-96. (Pubitemid 32641351)
7. Pao, W., Miller, V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23(11): 2556-68.
8. Sok, J.C., Coppelli, F.M., Thomas, S.M. et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006, 12(17): 5064-73. (Pubitemid 44453332)
9. Wang, X., Masri, S., Phung, S., Chen, S. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res 2008, 68(7): 2259-65. (Pubitemid 351521799)
10. Ciardiello, F., Tortora, G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358(11): 1160-74.
11. Paez, J.G., Janne, P.A., Lee, J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676): 1497-500. (Pubitemid 38720929)
12. Rosell, R., Carcereny, E., Gervais, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3): 239-46.
13. Mok, T.S., Wu, Y.L., Thongprasert, S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10): 947-57.
14. Maemondo, M., Inoue, A., Kobayashi, K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25): 2380-8.
15. Mitsudomi, T., Morita, S., Yatabe, Y. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2): 121-8.
16. Zhou, C., Wu, Y.L., Chen, G. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8): 735-42.
17. Nguyen, K.S., Kobayashi, S., Costa, D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10(4): 281-9.
18. Kobayashi, S., Boggon, T.J., Dayaram, T. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8): 786-92. (Pubitemid 40271173)
19. Maheswaran, S., Sequist, L.V., Nagrath, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4): 366-77.
20. Yun, C.H., Mengwasser, K.E., Toms, A.V. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105(6): 2070-5. (Pubitemid 351439466)
21. Solca, F., Dahl, G., Zoephel, A. et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343(2): 342-50.
22. Li, D., Ambrogio, L., Shimamura, T. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34): 4702-11.
23. Bean, J., Riely, G.J., Balak, M., Marks, J.L., Ladanyi, M., Miller, V.A., Pao, W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 14(22): 7519-25.
24. Mazieres, J., Peters, S., Lepage, B. et al. Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. J Clin Oncol 2013, 31(16): 1997-2003.
25. Ninomiya, T., Takigawa, N., Ichihara, E. et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 2013, 12(5): 589-97.
26. Schutze, C., Dorfler, A., Eicheler, W. et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007, 183(5): 256-64. (Pubitemid 46725991)
27. Tsai, Y.C., Yeh, C.H., Tzen, K.Y. et al. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer 2013, 49(6): 1458-66.
28. Ioannou, N., Dalgleish, A.G., Seddon, A.M., Mackintosh, D., Guertler, U., Solca, F., Modjtahedi, H. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011, 105(10): 1554-62.
29. Ioannou, N., Seddon, A.M., Dalgleish, A., Mackintosh, D., Modjtahedi, H. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVPAEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 2013, 13: 41.
30. Khelwatty, S.A., Essapen, S., Seddon, A.M., Modjtahedi, H. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 2011, 39(2): 483-91.
31. Eskens, F.A., Mom, C.H., Planting, A.S. et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008, 98(1): 80-5.
32. Yap, T.A., Vidal, L., Adam, J. et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28(25): 3965-72.
33. Gordon, M.S., Mendelson, D.S., Gross, M. et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs 2013, 31(2): 409-16.
34. Marshall, J., Hwang, J., Eskens, F.A. et al. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs 2013, 31(2): 399-408.
35. Stopfer, P., Marzin, K., Narjes, H., Gansser, D., Shahidi, M., Uttereuther-Fischer, M., Ebner, T. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012, 69(4): 1051-61.
36. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11): 783-92. (Pubitemid 32222155)
37. Miller, V.A., Hirsh, V., Cadranel, J. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13(5): 528-38.
38. Yang, J.C., Shih, J.Y., Su, W.C. et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13(5): 539-48.
39. Lin, N.U., Winer, E.P., Wheatley, D. et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012, 133(3): 1057-65.
40. ADAM-Afatinib Diarrhea Assessment and Management (NCT01814553). ClinicalTrials.gov Web site, Accessed September 16, 2013.
41. Murakami, H., Tamura, T., Takahashi, T. et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Luny 4). Cancer Chemother Pharmacol 2012, 69(4): 891-9.
42. Vermorken, J.B., Mesia, R., Rivera, F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11): 1116-27.
43. Bang, Y.J., Van Cutsem, E., Feyereislova, A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742): 687-97.
44. Pirker, R., Pereira, J.R., Szczesna, A. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674): 1525-31.
45. Vermorken, J.B., Rottey, S., Ehrnrooth, E., Palling, K., Lahogue, A., Wind, S., Machiels, J.P. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol 2013, 24(5): 1392-400.
46. Marshall, J., Shapiro, G.I., Uttenreuther-Fischer, M., Ould-Kaci, M., Stopfer, P., Gordon, M.S. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol 2013, 9(2): 271-81.
47. Awada, A.H., Dumez, H., Hendlisz, A. et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs 2013, 31(3): 734-41.
48. Chu, Q.S., Sangha, R.S., Hotte, S.J. et al. A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis. J Clin Oncol [49th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013] 2013, 31: Abst 2523.
49. Jackman, D., Pao, W., Riely, G.J. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28(2): 357-60.
50. Katakami, N., Atagi, S., Goto, K. et al. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013, 31(27): 3335-41.
51. Hirsh, V., Cadranel, J., Cong, X.J. et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013, 8(2): 229-37.
52. Schuler, M.H., Planchard, D., Yang, J.C. et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30: Abst 7557.
53. Sequist, L.V., Yang, J.C., Yamamoto, N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27): 3327-34.
54. Yang, J.C., Hirsh, V., Schuler, M. et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27): 3342-50.
55. Wu, Y.L., Zhou, C., Hu, C.P. et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplaiin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol [49th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013] 2013, 31: Abst 8016.
56. Seiwert, T., Fayette, J., Cupissol, D. et al. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck - Final data. Multidisciplinary Head and Neck Cancer Symposium (January 26-28, Phoenix) 2012, Abst LBPV10.
57. Cupissol, D., Seiwert, T.Y., Fayette, J., Ehrnrooth, E., Blackman, A.S., Cong, X.J., Cohen, E.E.W. A randomized, open-label, phase II study of afatinib versus cetuximab in atients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover. J Clin Oncol [49th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013] 2013, 31: Abst 6001.
58. Schuler, M., Awada, A., Harter, P. et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2012, 134(3): 1149-59.
59. Blackwell, K.L., Pegram, M.D., Tan-Chiu, E. et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009, 20(6): 1026-31.
60. Burstein, H.J., Sun, Y., Dirix, L.Y. et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28(8): 1301-7.
61. Kim, Y., Ko, J., Cui, Z. et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 2012, 11(3): 784-91.
62. Ercan, D., Zejnullahu, K., Yonesaka, K. et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29(16): 2346-56.
63. Yu, H.A., Arcila, M.E., Rekhtman, N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19(8): 2240-7.
64. Koizumi, H., Yamada, T., Takeuchi, S. et al. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol 2012, 7(7): 1078-85.
65. Yano, S., Yamada, T., Takeuchi, S. et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011, 6(12): 2011-7.
66. Zhang, Z., Lee, J.C., Lin, L. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012, 44(8): 852-60.
67. Li, R., Hu, Z., Sun, S.Y. et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther 2013, Advance publication.
68. Sequist, L.V., Waltman, B.A., Dias-Santagata, D. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75): 75ra26.
69. Witta, S.E., Gemmill, R.M., Hirsch, F.R. et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66(2): 944-50. (Pubitemid 43165962)
70. A study of intermittent, high-dose afatinib to determine the maximal tolerated dose and assess activity of this dose against non-small cell lung cancer with T790M mutations (NCT01647711). ClinicalTrials.gov Web site, Accessed September 16, 2013.
71. Trial of BIBW 2992 (afatinib) + cetuximab in non-small cell lung cancer (NCT01090011). ClinicalTrials.gov Web site, Accessed September 16, 2013.
72. Regales, L., Gong, Y., Shen, R. et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119(10): 3000-10.
73. Engelman, J.A., Zejnullahu, K., Gale, C.M. et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67(24): 11924-32.
74. Ramalingam, S.S., Blackhall, F., Krzakowski, M. et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012, 30(27): 3337-44.
75. Sequist, L.V., Besse, B., Lynch, T.J. et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(18): 3076-83.
76. Rabindran, S.K., Discafani, C.M., Rosfjord, E.G. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64(11): 3958-65. (Pubitemid 38697310)